Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000714153 | SCV000844836 | uncertain significance | not provided | 2019-03-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000714153 | SCV001216901 | likely pathogenic | not provided | 2024-11-07 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 178 of the UMOD protein (p.Arg178Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant tubulointerstitial kidney disease (PMID: 29212948; internal data). ClinVar contains an entry for this variant (Variation ID: 586921). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt UMOD protein function with a negative predictive value of 80%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Revvity Omics, |
RCV003133574 | SCV003814147 | likely pathogenic | Familial juvenile hyperuricemic nephropathy type 1 | 2022-04-26 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000714153 | SCV004226904 | likely pathogenic | not provided | 2023-03-16 | criteria provided, single submitter | clinical testing | PM2_supporting, PS3_moderate, PS4 |
Fulgent Genetics, |
RCV003133574 | SCV005638527 | pathogenic | Familial juvenile hyperuricemic nephropathy type 1 | 2024-06-20 | criteria provided, single submitter | clinical testing |